Prnewswire·2026-02-09 02:30Core Viewpoint - WuXi Biologics has been awarded the Platinum Medal by EcoVadis for the third consecutive year, recognizing its strong performance in sustainability and ESG practices [1][2]. Group 1: Sustainability Achievements - WuXi Biologics is ranked in the top 1% of over 150,000 companies evaluated globally, reflecting its robust ESG policies and performance outcomes validated by external stakeholders [2]. - The company has set near-term and net-zero GHG emissions reduction targets approved by the Science Based Targets initiative (SBTi), positioning it as a leader in the industry [3]. - WuXi Biologics launched a Green CRDMO White Paper detailing its green innovation technologies and showcasing significant carbon reductions achieved through its operations [4]. - The company has achieved ISO 20400 Sustainable Procurement certification, promoting sustainability principles in procurement practices [5]. Group 2: Leadership and Commitment - Dr. Chris Chen, CEO of WuXi Biologics, emphasized the company's commitment to advancing sustainability capabilities and enabling partners to meet their ESG goals [6]. - The achievement of the EcoVadis Platinum Medal reinforces global clients' confidence in WuXi Biologics' reliability and commitment to sustainability and compliance standards [7]. - WuXi Biologics actively participates in initiatives like the United Nations Global Compact and has received numerous recognitions, including an MSCI AAA Rating and inclusion in the Dow Jones Sustainability Indices [8]. Group 3: Company Overview - WuXi Biologics is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) providing end-to-end solutions for biologics [9]. - The company employs over 12,000 skilled professionals across multiple countries and supports 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing as of December 31, 2025 [10]. - WuXi Biologics integrates ESG responsibilities into its business strategy and aims to be a leader in the biologics CRDMO sector, utilizing next-generation biomanufacturing technologies [11].